The E211 G>A Androgen Receptor Polymorphism Is Associated With a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia

    April 2005 in “ Cancer Epidemiology, Biomarkers & Prevention ”
    Vanessa M. Hayes, Gianluca Severi, Sarah A. Eggleton, Emma J.D. Padilla, Melissa C. Southey, Robert L. Sutherland, John L. Hopper, Graham G. Giles
    Image of study
    TLDR E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.
    The E211 G>A Androgen Receptor Polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia, according to a study published in Cancer Epidemiology Biomarkers & Prevention in 2005. The study found that men with the E211 G>A polymorphism had a lower risk of developing metastatic prostate cancer and androgenetic alopecia compared to those without the polymorphism. The study included 1,056 men with prostate cancer and 1,267 controls. The study suggests that further investigation is needed to determine whether these associations can be attributed to linkage to one or both of the functional repeat sequences at the same loci.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 1000+ results

      community Maintaining hair until Breezula without Fin

      in Treatment  6 upvotes 4 years ago
      A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  41 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community A Technical Question About Pyrilutamide

      in Research/Science  5 upvotes 1 year ago
      Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 10 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Similar Research

    5 / 1000+ results